Developing Targeted Therapy for Patients with KRAS-driven Cancers

Kestrel is a clinical-stage biotechnology company focused on developing medicines for patients with intractable cancers driven by KRAS mutations.

Our goal has always been to use exceptional science to deliver transformative medicines with a focus on patients.

Potential to Treat Multiple Types of KRAS-driven Cancers ​

Mutations in the RAS family of genes (KRAS, HRAS and NRAS) are present in over 30% of all cancer. Activating mutations of the KRAS isoform, specifically, are observed in more than 20% of all cancers, making it one of the most frequently altered oncogenes. Kestrel’s goal is to develop best-in-class small molecule inhibitors that potently and selectively target KRAS regardless of the mutation or tumor type.

CT scan of a patient with metastatic pancreatic cancer. More than 95% of these tumors carry KRAS mutations, and most are presently not treatable.

Potent Activity Against Oncogenic KRAS

The KRAS protein is broadly implicated in cancer cell signaling processes and ultimately in the genesis of cancer. In its active, oncogenic configuration, KRAS is bound to GTP and is said to be in its ON state. We have developed novel chemical matter with excellent biophysical, biochemical and pharmacological characteristics. Our inhibitors are active against both the OFF and ON forms of KRAS, durably disrupt GTP-mediated signaling, and thereby effectively prevent its oncogenic actions.

Focus on Patients

KST-6051 is a potential best-in-class, oral pan-KRAS inhibitor that has been shown in pre-clinical testing to be effective against human tumors and well tolerated. Based on these findings, dosing has started in a Phase 1 study in patients with advanced cancers (NCT07458347).

Patients

KST-6051 in Patients

Kestrel Therapeutics has begun a Phase 1 study in patients with advanced or metastatic solid tumors with a locally assessed KRAS mutation.  Contact us to learn more about our study.

about us

Our Goal

Learn about our strategy to bring new therapy to cancer’s most frequently mutated oncogenic target, led by our Kestrel team, our Directors, and Advisory Board members.

Careers

Join Us

At Kestrel we recognize the success of our business depends upon the excellence of our people. We are dedicated to recruiting exceptional talent for our team.

Investors

News & Updates

Read our latest press releases and learn about our thought-leading investors.